Neoadjuvant imatinib: longer the better, need to modify risk stratification for adjuvant imatinib

BACKGROUND: Multimodality treatment of gastrointestinal stromal tumor (GIST) with surgery and adjuvant imatinib mesylate (IM), along with an emerging role for neoadjuvant IM prior to evaluation for resectability has resulted in high survival rates. METHODS: We conducted a retrospective analysis of p...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Gastrointest Oncol
Egile Nagusiak: Ramaswamy, Anant, Jain, Deepak, Sahu, Arvind, Ghosh, Joydeep, Prasad, Priya, Deodhar, Kedar, Shetty, Nitin, Banavali, Shripad, Shrikhande, Shailesh, Ostwal, Vikas
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AME Publishing Company 2016
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4963379/
https://ncbi.nlm.nih.gov/pubmed/27563454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2016.03.13
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak